Conditions:  Bladder Adenocarcinoma;  Bladder Clear Cell Adenocarcinoma;  Bladder Mixed Adenocarcinoma;  Bladder Neuroendocrine Carcinoma;  Bladder Small Cell Neuroendocrine Carcinoma;  Bladder Squamous Cell Carcinoma;  Bladder Urachal Adenocarcinoma;  Chromophobe Renal Cell Carcinoma;  Collecting Duct Carcinoma;  Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;  Infiltrating Bladder Urothelial Carcinoma;  Infiltrating Bladder Urothelial Carcinoma With Giant Cells;  Infiltrating Bladder Urothelial Carcinoma, Nested Variant;  Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;  Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;  Kidney Medullary Carcinoma;  Large Cell Neuroendocrine Carcinoma;  Metastatic Bladder Carcinoma;  Metastatic Bladder Large Cell Neuroendocrine Carcinoma;  Metastatic Bladder Small Cell Neuroendocrine Carcinoma;  Metastatic Bladder Squamous Cell Carcinoma;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;  Metastatic Kidney Medullary Carcinoma;  Metastatic Malignant Genitourinary System Neoplasm;  Metastatic Penile Carcinoma;  Metastatic Prostate Small Cell Neuroendocrine Carcinoma;  Metastatic Sarcomatoid Renal Cell Carcinoma;  Metastatic Urethral Carcinoma;  Papillary Renal Cell Carcinoma;  Sarcomatoid Renal Cell Carcinoma;  Stage IV Bladder Cancer AJCC v8;  Stage IV Penile Cancer AJCC v8;  Stage IV Prostate Cancer AJCC v8;  Stage IV Renal Cell Cancer AJCC v8;  Stage IV Urethral Cancer AJCC v8;  Stage IVA Bladder Cancer AJCC v8;  Stage IVA Prostate Cancer AJCC v8;  Stage IVB Bladder Cancer AJCC v8;  Stage IVB Prostate Cancer AJCC v8;  Testicular Leydig Cell Tumor;  Testicular Sertoli Cell Tumor;  Urethral Clear Cell Adenocarcinoma
Interventions:  Drug: Cabozantinib S-malate;  Biological: Ipilimumab;  Biological: Nivolumab
Sponsor:  National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions:  Drug: Cabozantinib S-malate;  Biological: Ipilimumab;  Biological: Nivolumab
Sponsor:  National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
